Clinical Trial Update: A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER) [Phase 3]

View source ↗

Summary

A Phase 3 trial (MASTER) evaluating the safety of an individualized combination therapy with ribavirin (Copegus) and peginterferon alfa-2a (Pegasys) for chronic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 3 | Status: WITHDRAWN